Clinical trials: Patients With Type 2 Diabetes
Diabetes in Adolescence, PreDiabetes
The Efficacy of AP029 Mix in Patients With Impaired Carbohydrate Metabolism
The aim of the study is to demonstrate that a daily supplementation of AP029 Mix: I) has a positive effect on reducing side effects of metformin, while enhancing the therapeutic effect of metformin; II) normalizes prediabetes…
- Trial name
- NCT05994586
- Testing
- AP029 mix
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- AronPharma Sp. z o. o.
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Patients With Type 1 or Type 2 Diabetes
This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia under normal clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01538589
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 1,582 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus
Rationale Rosiglitazone and troglitazone both promote differentiation of pre-adipocytes into adipocytes in subcutaneous, but not omental fat, and reduce gamma glutamyl transferase, a surrogate marker for intra-abdominal and…
- Trial name
- NCT01045590
- Testing
- titration
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes
Study objectives is to investigate the safety of long-term daily use of TRADIANCE® Combination Tablets AP and BP in Japanese patients with Type 2 Diabetes mellitus (T2DM) used in routine care.
- Trial name
- NCT03761797
- Testing
- TRADIANCE® Combination Tablets AP, TRADIANCE® Combination Tablets BP
- Where
- Japan
- Volunteers
- 1,164 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00918879
- Testing
- Saxagliptin
- Where
- 9 sites in India
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
The purpose of this study is to observe clinical effectiveness of canagliflozin by mean haemoglobin A1c (HbA1C) and body weight changes from baseline to 12 weeks in Indian type 2 diabetes participants.
- Trial name
- NCT03604224
- Testing
- Canagliflozin 300 mg
- Where
- 3 sites in India
- Volunteers
- 178 people
- Sponsor
- Johnson & Johnson Private Limited
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate pharmacokinetics, pharmacodynamics and safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- NCT01697618
- Testing
- biphasic insulin aspart 30, biphasic human insulin 30
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
T2DM (Type 2 Diabetes Mellitus)
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.
- Trial name
- SYMPHONY-1 (NCT06350890)
- Testing
- HTD1801
- Where
- 56 sites in China
- Volunteers
- 408 people
- Sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
Hypertension, Type 2 Diabetes Mellitus
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus
- Trial name
- NCT00744237
- Testing
- Nebivolol, Metoprolol ER, HCTZ
- Where
- 65 sites in United States, Puerto Rico
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Diabetes Mellitus, Type 2, Renal Insufficiency
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
This study will investigate the efficacy and safety of the BI 10773 in type 2 diabetic patients with renal impairment in order to provide these data for approval for BI 10773 as an antidiabetic agent by regulatory authorities.
- Trial name
- NCT01164501
- Testing
- BI 10773
- Where
- 127 sites in United States, Canada and 13 more
- Volunteers
- 741 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Renal Insufficiency
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal…
- Trial name
- NCT00765830
- Testing
- vildagliptin
- Where
- 90 sites in Argentina, Australia and 10 more
- Volunteers
- 349 people
- Sponsor
- Novartis
Diabetes, Diabetes Mellitus, Type 2
A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes
This trial is conducted in Europe. A seven day dose escalation study in subjects with type 2 diabetes.
- Trial name
- NCT00400283
- Testing
- NNC 55-0414
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
Primary Objective: To test the hypothesis that basal insulin based treatment (G+) is noninferior to twice-daily premixed insulin (PM-2) in term of hemoglobin A1c (glycosylated hemoglobin, HbA1c) reduction from baseline to end of…
- Trial name
- SWITCH (NCT03359837)
- Testing
- INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Sanofi
Diabetes Mellitus Type 2
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
This 4 arm study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of R1511 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00517465
- Testing
- RG1511
- Where
- 8 sites in Germany, Hungary and 2 more
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to sulfonylurea without or with metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-S (NCT00713830)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 16 sites in United States, Bulgaria and 14 more
- Volunteers
- 859 people
- Sponsor
- Sanofi
Diabetes Mellitus Type 2
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Primary Objective: To demonstrate the ease of use of the U300 pen injector in pen-naïve and insulin-naïve type 2 diabetes mellitus (T2DM) patients in a 4-week once-daily dosing regimen with HOE901-U300.
- Trial name
- NCT02227212
- Testing
- Insulin glargine U300 (new formulation of insulin glargine) HOE901
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
The purpose of this study is to look at the blood sugar control in participants with type 2 diabetes previously treated with premix insulins and initiating treatment with IDegLira.
- Trial name
- GLIDE (NCT05479591)
- Testing
- IDegLira
- Sponsor
- Novo Nordisk A/S
Congestive Heart Failure, Type II Diabetes Mellitus
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III).
- Trial name
- NCT00894868
- Testing
- vildagliptin
- Where
- 93 sites in Czechia, Denmark and 13 more
- Volunteers
- 798 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea
The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.
- Trial name
- NCT01903356
- Testing
- Trajenta duo
- Where
- South Korea
- Volunteers
- 724 people
- Sponsor
- Boehringer Ingelheim